This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Eficacy of Long-term Suplementation With Docosahexaenoic Acid in Patients With Cystic Fibrosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
ClinicalTrials.gov Identifier:
NCT01783613
First received: January 31, 2013
Last updated: April 25, 2017
Last verified: January 2015
  Purpose
Cystic Fibrosis (CF) is a congenital disease secondary to the abnormal function of CFTR. Patients with CF have an alteration of essential fatty acids, Arachidonic Acid (AA) is increased and Docosahexanoic Acid (DHA) is decrease and the ratio ω-6/ ω-3 is elevated, all these alterations stimulated a chronic and bad regulated state of inflammation. For this porpoise, a fase IV trial, multicentric, controlled, double blind, placebo and parallel in patients elder than two months old and randomized to received every day a dietetically supplement with DHA or placebo, will be done during 12 months. The trial has as a principal objective to proved if this long term supplementation could decrease in contrast with placebo.

Condition Intervention
Cystic Fibrosis Dietary Supplement: Docosahexaenoic acid administration: 50 mg/kg/day during 12 months Dietary Supplement: Placebo: 50 mg/kg/day during 12 months

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: Study of the Eficacy of Long-term Suplementation With Docosahexaenoic Acid on Pulmonary, Sistemic and Intestinal Inflammation in Patients With Cystic Fibrosis

Resource links provided by NLM:


Further study details as provided by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal:

Primary Outcome Measures:
  • To study whether long-term administration of DHA (12 months), at doses of 50 mg/ kg/day in patients over 2 months age diagnosed of CF decreases inflammation compared with placebo [ Time Frame: 12 months ]

Enrollment: 96
Study Start Date: October 2011
Study Completion Date: January 2015
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Docosahexaenoic acid administration
50 patients will receive docosahexaenoic acid
Dietary Supplement: Docosahexaenoic acid administration: 50 mg/kg/day during 12 months
Placebo Comparator: placebo
50 patients will receive placebo
Dietary Supplement: Placebo: 50 mg/kg/day during 12 months

  Eligibility

Ages Eligible for Study:   2 Months to 100 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed of cystic fibrosis over than 2 months age
  • Tolerance clinical supplementation with DHA
  • Clinical situation stable

Exclusion Criteria:

  • Changes in the routine treatment in the 2 weeks prior to baseline
  • Admission to hospital or administration of oral or intravenous antibiotics within 2 weeks before inclusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01783613

Locations
Spain
Hospital Universitario Central de Asturias
Oviedo, Asturias, Spain, 33006
Ramón y Cajal Hospital
Madrid, Spain, 28034
Hospital 12 de Octubre
Madrid, Spain, 28041
Hospital Universitario La Princesa
Madrid, Spain
Hospital Universitari i Politecnic La FE
Valencia, Spain, 46026
Sponsors and Collaborators
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
  More Information

Responsible Party: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
ClinicalTrials.gov Identifier: NCT01783613     History of Changes
Other Study ID Numbers: Docosahexaenoic acid
Study First Received: January 31, 2013
Last Updated: April 25, 2017

Additional relevant MeSH terms:
Fibrosis
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases

ClinicalTrials.gov processed this record on June 23, 2017